Patents-Review.com
🔗 Permalink
Assignee profile:

Beta Pharma, Inc.

City:

Wilmington, Delaware

Country:

United States

Published Applications:

13

Last publication date:

2022-11-03

Patent Grants:

13

Last grant date:

2025-08-19

Top Inventors for applications by Beta Pharma, Inc.

These are the the leading inventors for applications assigned to Beta Pharma, Inc.:

Recent patent applications by Beta Pharma, Inc.

Beta Pharma, Inc. based in Wilmington, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2022-11-03 ✅ Patent 12,390,464 granted on 2025-08-19
US20220347177A1
Human necessities

TREATMENT OF EGFR MUTANT-RELATED CANCERS USING A COMBINATION OF EGFR AND CDK4/6 INHIBITORS

 #2 | 2022-05-26 ✅ Patent 12,595,246 granted on 2026-04-07
US20220162185A1
Chemistry; metallurgy

CRYSTALLINE AND AMORPHOUS FORMS OF N-(5-((4-ETHYLPIPERAZIN-1-YL)METHYL)PYRIDINE-2-YL)-5-FLUORO-4-(3-ISOPROPYL-2-METHYL-2H-INDAZOL-5-YL)PYRIMIDIN-2-AMINE AND ITS SALTS, AND PREPARATION METHODS AND THERAPEUTIC USES THEREOF

 #3 | 2022-05-19 ✅ Patent 12,187,707 granted on 2025-01-07
US20220153726A1
Chemistry; metallurgy

Pharmaceutical formulations of -(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylaminde and salts thereof

 #4 | 2022-03-03 ✅ Patent 12,258,365 granted on 2025-03-25
US20220064194A1
Chemistry; metallurgy

Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof

 #5 | 2021-05-13 ✅ Patent 11,352,341 granted on 2022-06-07
US20210139459A1
Chemistry; metallurgy

2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof

 #6 | 2020-07-09 ✅ Patent 11,414,401 granted on 2022-08-16
US20200216421A1
Chemistry; metallurgy

Substituted 2-anilinopyrimidine derivatives as EGFR modulators

 #7 | 2020-04-30 ✅ Patent 11,180,478 granted on 2021-11-23
US20200131152A1
Chemistry; metallurgy

Pharmaceutical formulations of N-(2-(2-(dimethylamino) ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof

 #8 | 2019-12-05 ✅ Patent 11,052,086 granted on 2021-07-06
US20190365755A1
Human necessities

2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers

 #9 | 2019-08-01 ✅ Patent 10,844,045 granted on 2020-11-24
US20190233399A1
Chemistry; metallurgy

Pharmaceutical salts N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof

 #10 | 2018-05-31 ✅ Patent 10,239,864 granted on 2019-03-26
US20180148431A1
Chemistry; metallurgy

2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof

 #11 | 2017-12-21 ✅ Patent 10,590,111 granted on 2020-03-17
US20170362203A1
Chemistry; metallurgy

Substituted 2-anilinopyrimidine derivatives as EGFR modulators

 #12 | 2017-07-27 ✅ Patent 9,878,994 granted on 2018-01-30
US20170210726A1
Chemistry; metallurgy

2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof

 #13 | 2015-10-29 ✅ Patent 9,820,721 granted on 2017-11-21
US20150305724A1
Human necessities

Aspiration and biopsy needle apparatus and devices and applications thereof

Also check out Beta Pharma, Inc.'s (Wilmington, United States) applicant profile with 15 patent applications submitted.

AssigneeID:

124737 ⎘